Today, our firm is proud to announce that we have obtained a settlement from Johnson & Johnson on behalf of our client and his family. Our client grew female breasts in a condition called “gynecomastia” after taking Risperdal as a child, a drug that was only approved for adult use at the time. Risperdal’s manufacturers, Janssen Pharmaceuticals, said that gynecomastia was a rare side effect that only affected less than 1 in 1,000 patients.
After Johnson & Johnson were called to account for the high rate of gynecomastia cases, warning labels were updated to reflect the true number: more than 1 in 50 Risperdal users are likely to develop gynecomastia symptoms, not 1 in 1,000. That means Risperdal’s effects were over 20 times more likely to cause patients embarrassing and abnormal breast growth than the company originally reported.
This settlement resolves the seventh Risperdal case ever brought against Johnson & Johnson, but it is the second victory of two cases Arnold & Itkin has thus far brought forward. Our first Risperdal case against Johnson & Johnson resulted in a $76 million verdict in July 2016—a result far outweighing the $4.75 million won in total for 3 other cases tried by other law firms. It is still the largest victory of the Risperdal cases that have been tried so far.
However, litigation is far from over. Attorney Jason Itkin commented about what this means for future cases. He said, “Johnson & Johnson still faces thousands of claims by boys who grew female breasts as a result of taking Risperdal.” He added that this settlement does not mean Janssen will settle cases for other plaintiffs.
Just last month, a judge dismissed a case mid-trial for not sufficiently proving that Johnson & Johnson caused the plaintiff’s injuries. One of the earliest Risperdal cases resulted in a verdict in favor of the global pharmaceutical giant. It seems that Johnson & Johnson will still fight tooth and nail to not be held responsible.
Arnold & Itkin is proud to have won this settlement before trial even began. We are in the middle of preparing even more Risperdal cases, and we are confident that our firm will yet again successfully hold Johnson & Johnson accountable for the pain, suffering, and humiliation they’ve caused. Learn more about Risperdal here.